Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The company intends to respond to the two minor observations within the stipulated time
Gabapentin is indicated for the management of Postherpetic Neuraligia
The registered capital of the newly founded company is € 50 million
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The new campus has been designed as an employee-centred experience and ecosystem zone
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
Subscribe To Our Newsletter & Stay Updated
